Taysha completes dosing in REVEAL pivotal trial for TSHA-102 Rett syndrome therapy
Taysha Gene Therapies completed enrollment of 17 patients in its REVEAL pivotal trial for TSHA-102, with 100% of Phase 1/2 Part A patients achieving developmental milestones and no serious adverse events reported. The company expects topline interim data and FDA feedback on BLA s
View filing at SEC.gov →